Table 5.
Visual assessment scale (VAS) and frequency of TN attacks
| Study | Group |
VAS before therapy |
Frequency of TN attacks per day |
VAS at endpoint |
Follow-up |
Frequency of TN attacks at endpoint |
|---|---|---|---|---|---|---|
| Wu et al. [27] | BT-A | 7.05 (2.03) | 21.71 (22.68) | 1.8 | 2016 h 0 m 0 s | 2 |
| Placebo | (2.25) | 20.53 (10.38) | 5 | 19 | ||
| Shehata et al. [28] | BT-A | 8.3 | 36.7 (3.13) | 1.8 | 2016 h 0 m 0 s | 4 (7.12) |
| Placebo | 8.5 | 39.2 (3.05) | 8.2 | 36.1 (13.45) | ||
| Zúñiga et al. [29] | BT-A | 8.85 | 29.1 | 4.59 | 2664 h 0 m 0 s | 7.1 |
| Placebo | 8.19 | 31.06 | 6.94 | 21.25 | ||
| Zhang et al. [30] | BT-A (25 U) | 6.24 (2.13) | - | 2 | 1344 h 0 m 0 s | - |
| BT-A (75 U) | 7.18 (2.21) | - | 1.8 | - | ||
| Placebo | 6.96 (1.97) | - | 3.8 | - | ||
U = units per ml of solution; BT-A = botulinum toxin type A; TN = trigeminal neuralgia.